Bioxytran, Inc. (OTCMKTS:BIXT) Sees Large Decline in Short Interest

Bioxytran, Inc. (OTCMKTS:BIXT) was the target of a significant decline in short interest in April. As of April 15th, there was short interest totalling 7,900 shares, a decline of 86.0% from the March 31st total of 56,600 shares. Based on an average trading volume of 468,400 shares, the short-interest ratio is presently 0.0 days.

Bioxytran Stock Performance

Shares of OTCMKTS:BIXT traded down $0.02 during trading on Friday, hitting $0.12. The company’s stock had a trading volume of 88,741 shares, compared to its average volume of 175,213. The business has a 50 day moving average price of $0.12 and a two-hundred day moving average price of $0.13. The company has a market capitalization of $20.88 million, a PE ratio of -4.00 and a beta of -0.83. Bioxytran has a fifty-two week low of $0.07 and a fifty-two week high of $0.54.

Bioxytran (OTCMKTS:BIXT) last posted its quarterly earnings results on Friday, March 22nd. The company reported ($0.01) EPS for the quarter.

About Bioxytran

Bioxytran, Inc, a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.